Clinical trial
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
NCT03344094 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Mechanism of Action of Ocrelizumab in Multiple Sclerosis
- Lead sponsor
- University of Chicago
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 23, 2018
- Completion date
- April 10, 2019
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.